

This is a self-archived version of an original article. This version may differ from the original in pagination and typographic details.

Author(s): Paoli, John; Pölönen, Ilkka; Salmivuori, Mari; Räsänen, Janne; Zaar, Oscar; Polesie, Sam; Koskenmies, Sari; Pitkänen, Sari; Övermark, Meri; Isoherranen, Kirsi; Juteau, Susanna; Ranki, Annamari; Grönroos, Mari; Neittaanmäki, Noora

Title: Hyperspectral Imaging for Non-invasive Diagnostics of Melanocytic Lesions

Year: 2022

Version: Published version

Copyright: © The Authors 2022

Rights: CC BY-NC 4.0

Rights url: <https://creativecommons.org/licenses/by-nc/4.0/>

Please cite the original version:

Paoli, J., Pölönen, I., Salmivuori, M., Räsänen, J., Zaar, O., Polesie, S., Koskenmies, S., Pitkänen, S., Övermark, M., Isoherranen, K., Juteau, S., Ranki, A., Grönroos, M., & Neittaanmäki, N. (2022). Hyperspectral Imaging for Non-invasive Diagnostics of Melanocytic Lesions. *Acta Dermato-Venereologica*, 102, Article adv00815. <https://doi.org/10.2340/actadv.v102.2045>

Hyperspectral Imaging for Non-invasive Diagnostics of Melanocytic Lesions

John PAOLI^{1,2}, Ilkka PÖLÖNEN³, Mari SALMIVUORI^{4,5}, Janne RÄSÄNEN^{4,6}, Oscar ZAAR^{1,2}, Sam POLESIE^{1,2}, Sari KOSKENMIES⁵, Sari PITKÄNEN⁵, Meri ÖVERMARK⁵, Kirsi ISOHERRANEN⁵, Susanna JUTEAU⁷, Annamari RANKI⁵, Mari GRÖNROOS⁴ and Noora NEITTAANMÄKI^{1,8,9}

¹Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, ²Department of Dermatology and Venereology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Faculty of Information Technology, University of Jyväskylä, ⁴Department of Dermatology and Allergology, Päijät-Häme Social and Health Care Group, Lahti, ⁵Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, ⁶Department of Dermatology, Tampere University Hospital and Faculty of Medicine and Medical technology, Tampere University, Tampere, ⁷Department of Pathology, University of Helsinki and HUSLAB, Helsinki, Finland, ⁸Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg and ⁹Department of Clinical Pathology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

Malignant melanoma poses a clinical diagnostic problem, since a large number of benign lesions are excised to find a single melanoma. This study assessed the accuracy of a novel non-invasive diagnostic technology, hyperspectral imaging, for melanoma detection. Lesions were imaged prior to excision and histopathological analysis. A deep neural network algorithm was trained twice to distinguish between histopathologically verified malignant and benign melanocytic lesions and to classify the separate subgroups. Furthermore, 2 different approaches were used: a majority vote classification and a pixel-wise classification. The study included 325 lesions from 285 patients. Of these, 74 were invasive melanoma, 88 melanoma *in situ*, 115 dysplastic naevi, and 48 non-dysplastic naevi. The study included a training set of 358,800 pixels and a validation set of 7,313 pixels, which was then tested with a training set of 24,375 pixels. The majority vote classification achieved high overall sensitivity of 95% and a specificity of 92% (95% confidence interval (95% CI) 0.024–0.029) in differentiating malignant from benign lesions. In the pixel-wise classification, the overall sensitivity and specificity were both 82% (95% CI 0.005–0.005). When divided into 4 subgroups, the diagnostic accuracy was lower. Hyperspectral imaging provides high sensitivity and specificity in distinguishing between naevi and melanoma. This novel method still needs further validation.

Key words: hyperspectral imaging; non-invasive diagnostic; machine learning; malignant melanoma.

Accepted Oct 25, 2022; Epub ahead of print Oct 25, 2022

Acta Derm Venereol 2022; 102: adv00815.

DOI: 10.2340/actadv.v102.2045

Corr: Noora Neittaanmäki, Department of Clinical Pathology, Sahlgrenska University Hospital, Gula Stråket 8, SE-41345 Gothenburg, Sweden. E-mail: noora.neittaanmaki@fimnet.fi

Invasive malignant melanoma (MM) is the deadliest type of skin cancers with its prognosis related to the invasion depth (Breslow depth) at the time of diagnosis (1). With increasing incidence, the healthcare costs of MM are expected to expand dramatically (2). MM is

SIGNIFICANCE

To aid melanoma diagnostics, various non-invasive technologies have developed. Hyperspectral imaging is a novel non-invasive technology, which combines digital imaging, spectroscopy and the use of machine learning. The advantages include large field of view and rapid imaging process. This study assessed the accuracy of hyperspectral imaging in distinguishing between histopathologically verified naevi and melanomas. The results indicate that hyperspectral imaging is feasible for non-invasive diagnostics and provides high sensitivity and specificity. The novel method needs further validation with larger data-sets. The results will serve as a basis for future development of this novel imaging technique for commercial use.

the cost driver of skin cancers, with total annual costs of >90 million euros in Sweden (3). Earlier diagnosis could minimize these expenses, since the costs of melanoma *in situ* (MIS) without metastatic potential are significantly lower than those of advanced or metastasized MM (4).

The excisional biopsy and histopathological examination of suspicious pigmented lesions is the current gold standard for diagnosing MM. Even though early detection of MM is the best strategy to reduce mortality associated with melanoma, unnecessary excision of benign lesions increases morbidity and raises healthcare costs associated with melanoma screening (5). The number needed to excise, i.e. the number of excised lesions per diagnosed melanoma varies from >20 for primary care to 6 for pigmented lesion specialists (6). A differential diagnostic problem for melanomas are benign pigmented lesions, including dysplastic naevi (DN) and other non-dysplastic benign naevi (BN), which can resemble early MM or MIS clinically (7). There is therefore a demand for objective and non-invasive examination methods to aid the clinicians in deciding which lesions to excise.

Hyperspectral imaging (HI) is a novel non-invasive imaging technique, which combines digital imaging, spectroscopy and the use of machine learning (ML) to provide automated diagnostic classifications. Unlike human colour vision, which is limited by the trichro-

matic colour system to detect the wavelengths of visual light (380–740 nm), HI can provide information from wavelengths not visible by humans. A hyperspectral image is a stack of hundreds of overlapping images taken at different narrow wavebands of light. The resulting hyperspectral cube contains 2 spatial dimensions and the spectral data for every pixel provides a third dimension. The technique can be used for diagnostic purposes (8, 9) or to visualize tumour borders (10, 11).

This study sought to determine the accuracy of a HI system combined with a novel 3-dimensional (3D) deep learning method in the non-invasive diagnosis of melanocytic lesions.

MATERIALS AND METHODS

Recruitment

The study protocol followed the principles of the Declaration of Helsinki and was approved by local ethics committees in both Gothenburg and Tampere (approval numbers 283-18 and R14120). Patients were recruited prospectively at 2 study centres in Finland (the Department of Dermatology of Helsinki University Hospital in Helsinki and the Päijät-Häme Central Hospital in Lahti) between June 2016 and October 2017 and at Sahlgrenska University Hospital in Gothenburg, Sweden between June 2018 and December 2019.

The inclusion criterion was any clinically atypical melanocytic lesion that was scheduled for excision and subsequent histopathological analysis.

Image acquisition and sampling for histopathology

The lesions were first photographed and evaluated with a dermatoscope by a dermatologist. Hyperspectral images were taken *in vivo* using 3 similar HI system prototypes (HSCP2, Revenio group, Finland). The system consists of a Fabry-Pérot interferometer (FPI) based hyperspectral imager and diffuse illumination system (12). The use of an FPI enables fast scanning in the spectral domain. The imager captures 120 wavebands rapidly in seconds using the diffuse reflectance of visible and near-infrared light (wavebands 450–900 nm) within a large field of view (FOV) of 12 cm² (spatial resolution 6,400 pixels/cm). The imaging depth of HI depends on the wavelength (13). In the used wavelength range, the imaging depth varies between 0.5 and 5 mm as a function of wavelength. The full width of each waveband's half maximum varies from 5 to 15 nm. The camera used is capable to taking images at a resolution of 1,920×1,200 pixels. This corresponds to approximately 15 μm/pixel spatial resolution. Before each hyperspectral image was acquired, an image from a white reference standard was obtained. The detailed description of the HI technique is available elsewhere (8, 10, 11).

After imaging, the lesions were excised and processed for routine histopathological examination. The specimens were fixed in 4% formalin, embedded in paraffin, sectioned using the traditional vertical bread loaf technique and stained with haematoxylin-eosin (H&E). All samples were assessed by dermatopathologists and the histopathological diagnoses of the excised specimens were considered as the true label for the data-set.

Data processing

Based on the histopathological reports, a dermatologist (JP) and dermatopathologist (NN) manually annotated each image and categorized them according to 5 classes: healthy skin, BN, DN, MIS, and MM.

The mathematical modelling was performed by a mathematician (IP). A supervised ML approach was used to train a deep neural network algorithm to distinguish between the different lesion types. The neural network used in this study was modified from Hyper3Dnet, a network which utilizes both 3D and 2-dimensional convolutional layers, extracting features from both spectral and spatial domains (14). To increase the sample size, we chose to train a pixel-wise classification algorithm. The images were divided vertically in the middle of the annotated lesion similarly to the method used by Räsänen et al. (9). The left side was used to train the algorithm and validate the training process. The right side was used to test classification performance. This ensured firstly that the training or validation set did not contain data-points from the image currently being classified, and, secondly, that the training set contained a sufficient variation of different lesion types (15–17). In the pixel-wise analysis this approach made pixels training and test sets independent and reduced the effect of spatial autocorrelation (18). From the left side of each of the images, 50 pixels from the healthy area and 100 pixels from the annotated lesion area were randomly selected for training and validation. For each pixel, a 25×25×55 window was collected, where the first 2 variables correspond to the spatial domain and the last 1 to the spectral domain. The analysis included every second band in the spectral domain in order to reduce the amount of data for processing. This data-set was then randomly divided into the training set (41,437 samples) and the validation set (7,313 samples). There was a slight imbalance between classes in the training set. Classes were balanced using the random over-sampling method (19), which increased the amount of training data to 89,700 samples. Data augmentation was performed by rotating images 3 times 90° in the spatial domain (20). This multiplied the training set by a factor of 4 (358,800 samples). For testing, a total of 24,375 pixels from the right halves of the images was selected.

Before the actual training, effects of vignetting and curvature of the skin surface were reduced by normalizing reflectance from images subject to the spectral mean, i.e. where λ_i denotes different wavebands. Here $R(\lambda_i)$ is reflectance spectra for the each pixel. Reflectance $R(\lambda_i) = I(\lambda_i)/I_0(\lambda_i)$, where I is measured radiance and I_0 is irradiance of the light source, which is measured by imaging white Teflon target. $R(\lambda_i)$ is single waveband image. This is normalizing data in such a way that the mean of each spectrum is 0.

Training was performed using Hyper3Dnet with modifications to the encoder part of the architecture (14) where only 16 filters were used, and the dense layer had only 256 nodes. Training used an Adam optimizer with a learning rate of 0.0001, a momentum term β_1 of 0.9, a momentum term β_2 of 0.999, and an epsilon value of 10×10^{-8} . The algorithm was implemented using Python 3.6 (<https://www.python.org>) and Tensorflow 2.0 (tensorflow.org). For computing, a Tesla P100-PCIE-16GB general-purpose graphics processing unit (Tesla, Nvidia, UK) was used. For training, 60 epochs on mini-batches (size 64) were computed. Categorical cross-entropy was used for loss function.

Two different approaches were used: (i) the majority of the pixels per lesion "majority vote" classification; and (ii) the pixel-wise classification. In the majority vote classification, the class was determined by selecting pixels from the annotated right half of the lesional area and counted to which class the majority of pixels in this area belonged. The classification result was true positive if most predictions were in the same class as the ground truth (the annotated masks based on histopathology). In the pixel-wise classification, each tested pixel was seen as an independent sample. Both models were trained twice: for 2 class classification to distinguish benign (BN+DN) and malignant lesions (MIS+MM) and to classify different lesion types. The pixel-wise classification also included pixels from the annotated healthy skin regions surrounding the lesional area and resulted in either 3 classes (healthy, benign or malignant) or 5 classes (healthy, BN, DN, MIS, MM) while the majority vote only analysed the lesional area and resulted

Table I. Results of the majority vote classification

Majority vote	Class	Sensitivity	Specificity	95% CI
Two classes	Benign	0.97	0.89	0.0185–0.034
	Malignant	0.93	0.96	0.028–0.021
Four classes	OA	0.95	0.92	0.024–0.029
	BN	0.95	0.80	0.024–0.043
	DN	0.99	0.70	0.011–0.050
	MIS	0.85	0.93	0.039–0.028
	MM	0.71	0.99	0.049–0.011
	OA	0.88	0.84	0.035–0.040

In the 2 class analyses, the benign group included both dysplastic naevi (DN) and non-dysplastic benign naevus (BN), while the malignant group included melanoma *in situ* (MIS) and invasive melanomas (MM).

95% CI: 95% confidence interval; OA: overall accuracy (bold).

in either 2 classes (benign vs malignant) or 4 classes (BN, DN, MIS and MM).

RESULTS

In total, 364 melanocytic lesions were imaged in the 3 study centres. In 39 cases, the HI system settings were not optimal at the time of imaging and the images were excluded due to imaging artefacts. Thus, 325 lesions in 285 patients were included in the study.

Lesion characteristics and histopathological diagnoses

The mean diameter of the lesions was 9.4 mm (range 3–50 mm). All the lesions fitted the FOV and could be imaged in 1 session. The malignant lesions (MM+MIS)

Table II. Results of the pixel-wise classification

Pixel-wise	Class	Sensitivity	Specificity	95% CI
Three classes	Healthy	0.88	0.85	0.004–0.004
	Benign	0.81	0.78	0.005–0.005
	Malignant	0.76	0.81	0.005–0.005
Five classes	OA	0.82	0.82	0.005–0.005
	Healthy	0.90	0.82	0.004–0.005
	BN	0.71	0.62	0.006–0.006
	DN	0.85	0.59	0.005–0.006
	MIS	0.62	0.73	0.006–0.004
MM	0.55	0.86	0.006–0.004	
	OA	0.77	0.74	0.005–0.006

In the 2 class analyses, the benign group included both dysplastic naevi (DN) and non-dysplastic benign naevus (BN), while the malignant group included melanoma *in situ* (MIS) and invasive melanomas (MM).

95% CI: 95% confidence interval; OA: overall accuracy (bold).

were larger than the benign lesions (DN+BN) with a mean diameter of 11.5 mm (range 4–50) and 7.2 (range 3–16), respectively, $p < 0.05$. The majority of the imaged lesions were located on the torso (53.5 % $n = 174$), and on the extremities (40.9%, $n = 133$), while only 5.5 % ($n = 18$) were in the head and neck region.

Histopathological diagnoses were: 74 MMs, 88 MIS, 115 DN, and 48 BN. The mean Breslow thickness of the MMs was 1.2 mm (range 0.2–6.3). The MMs were of the following subtypes: superficial spreading ($n = 52$), lentigo maligna melanoma ($n = 9$), melanoma associated with a naevus ($n = 6$), nodular melanoma ($n = 3$) and unclassified ($n = 3$). Of the DN, 81 showed low-grade dysplasia and 21




Fig. 1. Majority vote classification. The number of lesions in each class is shown in the confusion matrix below. BN: benign nevus; DN: dysplastic nevus; MM: malignant melanoma; MIS: melanoma *in situ*.

Fig. 2. Pixel-wise classification. The number of pixels in each class is shown in the confusion matrix below. BN: benign nevus; DN: dysplastic nevus; MM: malignant melanoma; MIS: melanoma *in situ*.

high-grade dysplasia. In 6 cases, the grade was not reported. Among the BN, the diagnoses were mainly compound naevi ($n=27$), junctional naevi ($n=5$), intradermal naevi ($n=5$) and blue naevi ($n=5$). There was also 1 case each of: congenital naevus, Reed naevus, spindle cell naevus, deep penetrating naevus, and special site naevus.

Hyperspectral analysis

Majority vote classification. In the majority vote analysis, the annotated right half of the lesions were analysed, and which class the majority of pixels in this area belonged to was counted. The classification result was true positive if most predictions were in the same class as the ground truth (the annotated masks based on histopathology). In 2 classes analyses for benign (BN+DN) vs malignant (MIS+MM), the overall sensitivity was 0.95 and specificity 0.92 (95% CI 0.024–0.029). Overall sensitivity for 4 classes (BN, DN, MIS, MM) was 0.88 and specificity 0.84 (95% CI 0.035–0.040) (Table I, Fig. 1).

Pixel-wise classification. In the pixel-wise classification, the model was trained based on independent pixels of the image. Each tested pixel on the right lesion halves was seen as an independent sample and the class was determined separately for each pixel. Pixels from the annotated lesional area and healthy skin surrounding the lesions were included. Overall accuracy of pixel-wise classification for 3 classes (healthy, benign, malignant) was 0.82 for both sensitivity and specificity (95% CI 0.005–0.005), while for 5 classes (healthy, BN, DN, MIS, MM) the overall sensitivity was 0.77 and specificity was 0.74 (95% CI 0.005–0.006) (Table II, Fig. 2).

Both the pixel-wise and the majority vote approaches offered not only classification, but also delineation, and a map-like representation of the lesions as is shown in Figs 3–4. Mean spectra and standard deviation (SD) for healthy skin and different lesions are shown in Fig. 5.

DISCUSSION

In this study, HI showed its potential for the non-invasive diagnosis of naevi and melanoma. The most reliable results were achieved when using the majority vote method for differentiating benign (BN+DN) vs malignant (MIS+MM) melanocytic lesions. This analysis achieved higher overall sensitivity 95% and specificity 92% than the pixel-wise analysis for (82% overall sensitivity and specificity). The classifications into histological subclasses (BN, DN, MIS, MM) showed somewhat lower overall accuracy with both methods, which could be explained by a lower number of cases and pixels when dividing the material into subgroups.

Previously, we have shown HI to be useful in differentiating between MM and pigmented basal cell carcinoma (BCC) and thus shown capability in differentiating tumours of melanocytic and keratinocytic origin (9). Furthermore, HI can offer a tool for detecting invasive parts of larger melanocytic lesions, such as lentigo maligna melanoma, which could allow for targeted biopsies (8). We have also shown that map-like HI images can be used preoperatively in the delineation of both melanocytic and non-melanocytic malignant tumours (10, 11). The advantages of HI include: (i) a combination of digital imaging and spectroscopy, i.e. spectral data can be obtained from map-like images; (ii) a large imaging field (12 cm²) and (iii) a rapid imaging process (s) and automated analysis performed on visual data. Although there is no commercial HI device available currently, the technique could be especially useful for an inexperienced physician, since it is not user-dependent and could potentially provide an automated diagnosis. HI could potentially decrease the number needed to excise among general practitioners, and even among dermatologists, and help to determine which lesions should be excised and which could be followed.




Fig. 3. Classification and likelihood maps for a histopathologically verified invasive melanoma (MM) (left) and non-dysplastic benign naevus (BN) (right), pixel-wise method, 5 classes. (a, j) Red-green-blue (RGB) image taken by the hyperspectral imaging (HI) camera, (b, k), annotation mask, (c, l) classification map, (d, m) a likelihood map for localization of healthy skin (e, n) a likelihood map for localization of BN, (f, o) a likelihood map for localization of dysplastic naevi (DN), (g, p) a likelihood map for localization of melanoma *in situ* (MIS), (h, q) a likelihood map for localization of a MM.




Fig. 4. Classification and likelihood maps for a histopathologically verified MIS (pixel-wise method, 5 classes). (a) Red-green-blue (RGB) image taken by hyperspectral imaging (HI), (b) annotation mask, (c) classification map showing most of the pixels correctly classified as melanoma *in situ* (MIS), but some showing invasive melanoma (MM), (d) a likelihood map for localization of healthy skin, (e) a likelihood map for localization of non-dysplastic benign naevus (BN), (f) a likelihood map for localization of dysplastic naevi (DN), (g) a likelihood map for localization of MIS, (h) a likelihood map for localization of MM. HIS differed from the annotation based on the histopathological interpretation. It cannot be completely ruled out that a small area of MM could have been missed in the histopathological interpretation.

To aid melanoma diagnostics, various other non-invasive imaging methods have been developed, including digital dermoscopy, reflectance confocal microscopy (RCM), high-resolution optical coherence tomography (HR-OCT), multiphoton laser scanning microscopy (MLT), electrical impedance spectroscopy, Raman spectroscopy and multispectral imaging (21–36). Many of these techniques are based on spectral technologies (37). The advantages of the proposed HI method compared with some other spectral techniques, such as Raman spectroscopy, include the possibility to obtain the spectral data from an image. The large FOV makes the HI fast and enables imaging even larger lesions at once. This is a clear advantage compared with RCM or MLT.

The maplike images can also be used preoperatively in the delineation of the lesions (10, 11). Furthermore, HI gives automated analysis performing visual data, which makes it simple to use and not user dependent. This is an advantage compared with extensive training and knowledge about histopathology needed for the use of some high-resolution techniques, such as RCM or HR-OCT. A disadvantage compared with the high resolution techniques is the poorer resolution. While RCM, MLT and HR-OCT are able to detect intracellular structures, HIS is limited to cell aggregates. However, we believe this resolution combined to the spectral data obtained with HI is good enough to achieve acceptable diagnostic accuracy for skin tumour diagnostics. Imaging depth




Fig. 5. Mean spectra (black line) and standard deviation (red area) for healthy skin, benign naevi (BN), dysplastic naevi (DN), melanoma *in situ* (MIS) and invasive melanoma (MM).

with HI is approximately 2 mm, which is better than the high-resolution devices that typically reach the papillary dermis. The technique most similar to HI is multispectral imaging (MI) which unlike HI (which takes tens to hundreds of images with narrow continuous wavebands) takes 5–15 separate images using non-continuous wide spectral bands (37). In previous studies, MI using commercial products, such as Melafind (MELA Sciences, Irvington, NY, USA) and Siascope (MedX Headquarters, ON, Canada), has achieved varying sensitivity of 83–98% and specificity of 8–91% in melanoma diagnostics (38). In a recently published study, another HI system including 202 pigmented skin lesions achieved 96.7% sensitivity to detect MM and a specificity of 42.1% for benign lesions (39). The current study had a larger sample size and 2 further developed analysing techniques, which resulted in increased accuracy compared with this study. Interestingly, there are HI systems that can be attached to light microscopes for obtaining hyperspectral histopathology images of H&E-stained melanoma tissue for tumour detection from healthy skin and for measurement of the invasion depth (Breslow thickness) (40, 41).

Study limitations

Limitations of the current study include the limited number of imaged lesions. Nevertheless, the use of a pixel-wise approach increased the data-set dramatically, since in this method every single pixel was seen as an independent "lesion". The algorithm used for the data analysis was a novel modification of deep neural network analysis that still needs further development. In the majority vote analysis, the fact that the current study used half of each lesion for training/validation and the other half for analysis could potentially have affected the results. This approach was used due to the limited sample size and large variation in the imaged lesions. However, the pixel-wise analysis overcame this potential bias. Since some images had to be excluded due to the low quality, the HI system prototypes also still need adjustments in order to avoid imaging artefacts. Even though there was variation in the lesion size, with naevi being smaller than MM on average, the approach of using pixel-wise classification overcame this potential bias. Furthermore, experience is needed in imaging different body parts, for example acral melanomas and naevi of special sites, since skin topography in these areas varies and can complicate image acquisition. The current study material also lacked Spitzoid lesions and rare melanoma subtypes. Furthermore, other pigmented lesions including pigmented BCCs and seborrhoeic keratoses, dermatofibromas, benign lentiginosities should be included in the differential diagnoses and this needs further study. Moreover, patients in this investigation were recruited from 2 Nordic countries, meaning that most patients had fair skin phototypes. Another limitation is that the

current study did not collect the specific skin phototypes and that the images were taken at different seasons of the year, which may have affected the skin pigmentation. To examine the external validity of our findings, future investigations should also target other populations with more pigmented skin.

Both analytical methods have their limitations. The majority vote classification gives only 1 diagnosis per lesion and could potentially miss a small melanoma associated with a large naevus or a small invasive component within a larger MIS. The pixel-wise classification gives a more realistic picture, mimicking the histopathology of the lesion, showing a classification for each pixel and resulting in mixed lesion types. However, these mixed images may be confusing for clinicians to interpret.

HI cannot replace the gold standard of histopathological evaluation of melanoma, including assessment of the lesion thickness, ulceration, regression and mitotic rate. However, since image acquisition with HI is performed with different wavelengths and different penetration depths, imaging could be adjusted to also measure lesion thickness by providing 4-dimensional information (3 spatial dimensions and the spectral dimension). Interestingly, the classification maps showed a combination of spectra within the same lesion in some cases as was depicted in Fig. 4. It is therefore possible that HI could detect areas of interest that could have been missed in the histopathological analysis. Theoretically, it is therefore also possible, that minimally invasive melanomas may have been missed in the routine histopathological sectioning of the specimen and HI may actually have classified 1 or more invasive melanomas correctly. Further studies with larger data-sets are thus warranted.

Conclusion

In this study, HI showed its potential in the non-invasive diagnosis of melanocytic tumours with relatively high sensitivity, specificity, and overall accuracy.

ACKNOWLEDGEMENT

This study was funded by the Instrumentarium Foundation, by the Finnish Cancer foundation, by the Finnish Dermatopathology society, by the Hudfonden Foundation and by the Academy of Finland.

Conflicts of interest. The authors NN, IP and MG are patent holders for the patent US 10478071 regarding hyperspectral imaging. MG has received consultation fee from the Revenio group. The Revenio group kindly loaned the hyperspectral imaging devices for the study.

REFERENCES

1. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin* 2017; 67: 472–492.

2. Gordon LG, Rowell D. Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review. *Eur J Cancer Prev* 2015; 24: 141–149.
3. Eriksson T, Tinghög G. Societal cost of skin cancer in Sweden in 2011. *Acta Derm Venereol* 2015; 95: 347–348.
4. Alexandrescu DT. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages. *Dermatol Online J* 2009; 15: 1.
5. Baade PD, Youl PH, Janda M, Whiteman DC, Del Mar CB, Aitken JF. Factors associated with the number of lesions excised for each skin cancer: a study of primary care physicians in Queensland, Australia. *Arch Dermatol* 2008; 144: 1468–1476.
6. Petty AJ, Ackerson B, Garza R, Peterson M, Liu B, Green C, et al. Meta-analysis of number needed to treat for diagnosis of melanoma by clinical setting. *J Am Acad Dermatol* 2020; 82: 1158–1165.
7. Terushkin V, Ng E, Stein JA, Katz S, Cohen DE, Meehan S, et al. A prospective study evaluating the utility of a 2-mm biopsy margin for complete removal of histologically atypical (dysplastic) nevi. *J Am Acad Dermatol* 2017; 77: 1096–1099.
8. Neittaanmäki N, Salmivuori M, Pölönen I, Jeskanen L, Ranki A, Saksela O, et al. Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma. *Br J Dermatol* 2017; 177: 1742–1744.
9. Räsänen J, Salmivuori M, Pölönen I, Grönroos M, Neittaanmäki N. Hyperspectral imaging reveals spectral differences and can distinguish malignant melanoma from pigmented basal cell carcinomas: a pilot study. *Acta Derm Venereol* 2021; 101: adv00405.
10. Neittaanmäki-Perttu N, Grönroos M, Jeskanen L, Pölönen I, Ranki A, Saksela O, Snellman E. Delineating margins of lentigo maligna using a hyperspectral imaging system. *Acta Derm Venereol* 2015; 95: 549–552.
11. Salmivuori M, Neittaanmäki N, Pölönen I, Jeskanen L, Snellman E, Grönroos M. Hyperspectral imaging system in the delineation of ill-defined basal cell carcinomas: a pilot study. *J Eur Acad Dermatol Venereol* 2019; 33: 71–78.
12. Saari H, Pölönen I, Salo H, Honkavaara E, Hakala T, Holmlund C, et al. Miniaturized hyperspectral imager calibration and UAV flight campaigns. *International Society for Optics and Photonics. Sensors, Systems, and Next-Generation Satellites XVII* 2013; 8889: 88891.
13. Barun VV, Ivanov AP, Volotovskaya AV. Absorption spectra and light penetration depth of normal and pathologically altered human skin. *J Appl Spectrosc* 2007; 74: 430–439.
14. Morales G, Sheppard JW, Scherrer B, Shaw JA. Reduced-cost hyperspectral convolutional neural networks. *J Appl Remote Sens* 2020; 14: 036519.
15. Audebert N, Le Saux B, Lefèvre S. Deep learning for classification of hyperspectral data: a comparative review. *IEEE Geoscience and Remote Sensing Magazine* 2009; 7: 159–173.
16. Lunga D, Prasad S, Crawford MM, Ersoy O. Manifold-learning-based feature extraction for classification of hyperspectral data: A review of advances in manifold learning. *IEEE Signal Processing Magazine* 2013; 31: 55–66.
17. Ghamisi P, Plaza J, Chen Y, Li J, Plaza, AJ. Advanced spectral classifiers for hyperspectral images: a review. *IEEE Geoscience and Remote Sensing Magazine* 2017; 5: 8–32.
18. Legendre P. Spatial autocorrelation: trouble or new paradigm? *Ecology* 1993; 74: 1659–1673.
19. Menardi, G, Torelli N. Training and assessing classification rules with imbalanced data. *Data Mining and Knowledge Discovery* 2014; 28: 92–122.
20. Goodfellow I, Bengio Y, Courville A, Bengio Y. *Deep learning*. Cambridge: MIT Press; 2016.
21. Heal CF, Raasch BA, Buettner PG, Weedon D. Accuracy of clinical diagnosis of skin lesions. *Br J Dermatol* 2008; 159: 661–668.
22. Langley RG, Walsh N, Sutherland AE, Propperova I, Delaney L, Morris SF, et al. The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective study. *Dermatology* 2007; 215: 365–372.
23. Ferris LK, Harris RJ. New diagnostic aids for melanoma. *Dermatol Clin* 2012; 30: 535–545.
24. Tkaczyk E. Innovations and developments in dermatologic non-invasive optical imaging and potential clinical applications. *Acta Derm Venereol* 2017; Suppl 218: 5–13.
25. Gambichler T, Plura I, Schmid-Wendtner M, Valavanis K, Kulichova D, Stücker M, et al. High-definition optical coherence tomography of melanocytic skin lesions. *J Biophotonics* 2015; 8: 681–686.
26. Dimitrow E, Ziemer M, Koehler MJ, Norgauer J, König K, El-sner P, et al. Sensitivity and specificity of multiphoton laser tomography for in vivo and ex vivo diagnosis of malignant melanoma. *J Invest Dermatol* 2009; 129: 1752–1758.
27. Mohr P, Birgersson U, Berking C, Henderson C, Trefzer U, Kemeny L, et al. Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma. *Skin Res Technol* 2013; 19: 75–83.
28. Malvey J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, et al. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. *Br J Dermatol* 2014; 171: 1099–1107.
29. Friedman RJ, Gutkowitz-Krusin D, Farber MJ, Warycha M, Schneider-Kels L, Papastathis N, et al. The diagnostic performance of expert dermoscopists vs a computer-vision system on small-diameter melanomas. *Arch Dermatol* 2008; 144: 476–482.
30. Monheit G, Cognetta AB, Ferris L, Rabinovitz H, Gross K, Martini M, et al. The performance of MelaFind: a prospective multicenter study. *Arch Dermatol* 2011; 147: 188–194.
31. Glud M, Gniadecki R, Drzewiecki KT. Spectrophotometric intracutaneous analysis versus dermoscopy for the diagnosis of pigmented skin lesions: prospective, double-blind study in a secondary reference centre. *Melanoma Res* 2009; 19: 176–179.
32. Moncrieff M, Cotton S, Claridge E, Hall P. Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. *Br J Dermatol* 2002; 146: 448–457.
33. Tomatis S, Carrara M, Bono A, Bartoli C, Lualdi M, Tragni G, et al. Automated melanoma detection with a novel multispectral imaging system: results of a prospective study. *Phys Med Biol* 2005; 50: 1675–1687.
34. Marghoob AA, Swindle LD, Moricz CZ, Sanchez Negron FA, Slue B, Halpern AC, et al. Instruments and new technologies for the in vivo diagnosis of melanoma. *J Am Acad Dermatol* 2003; 49: 777–797.
35. Fink C, Haenssle HA. Non-invasive tools for the diagnosis of cutaneous melanoma. *Skin Res Technol* 2017; 23: 261–271.
36. Meng X, Chen J, Zhang Z, Li K, Li J, Yu Z, et al. Non-invasive optical methods for melanoma diagnosis. *Photodiagnosis Photodyn Ther* 2021; 34: 102266.
37. Li Q, He X, Wang Y, Liu H, Xu D, Guo F. Review of spectral imaging technology in biomedical engineering: achievements and challenges. *J Biomed Opt* 2013; 18: 100901.
38. March J, Hand M, Grossman D. Practical application of new technologies for melanoma diagnosis: Part I. Noninvasive approaches. *J Am Acad Dermatol* 2015; 72: 929–941.
39. Christensen GB, Nagaoka T, Kiyohara Y, Johansson I, Ingvar C, Nakamura A, et al. Clinical performance of a novel hyperspectral imaging device for cutaneous melanoma and pigmented skin lesions in Caucasian skin. *Skin Res Technol* 2021; 27: 803–809.
40. Wang Q, Sun L, Wang Y, Zhou M, Hu M, Chen J, et al. Identification of melanoma from hyperspectral pathology image using 3D convolutional networks. *IEEE Trans Med Imaging* 2021; 40: 218–227.
41. Wang J, Li Q, Zhou M, Sun L, Hu M, Lyu Y, et al. Identification and measurement on cutaneous melanoma superficial spreading depth using microscopic hyperspectral imaging technology. *J Infrared Millim Waves* 2020; 39: 749–759.